Skip to content

MICHL-trial: Impact of Peritoneal Bladder Flap in RARP Patients on Lymphoceles

Prospective Randomised Study to Examine the Influence of a Modification of the DaVinci Prostatectomy on the Frequency of Postoperative Lymphoceles Requiring Treatment and Postoperative Complications

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06284135
Enrollment
1080
Registered
2024-02-28
Start date
2017-06-19
Completion date
2021-05-31
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphocele After Surgical Procedure

Keywords

prostate cancer, radical prostatectomy, pelvic lymph node dissection, lymphocele, complication

Brief summary

A two-armed prospective randomised, controlled, single-centre trial on 1080 patients with prostate cancer who underwent robot-assisted radical prostatectomy with bilateral pelvic lymph node dissection was carried out. Patients in the intervention arm received fixation of the peritoneal flap of the bladder to the plexus Santorini at the end of surgery (Michl-technique, MT); in the control group, surgery was performed without this modification. The primary endpoint was the rate of lymphoceles requiring intervention.

Interventions

OTHERMichl-stitch

In the intervention group, a ventral fixation was performed by suturing the ventral bladder peritoneum to the plexus Santorini and from there to the right and left lateral endopelvic fascia (MICHL-stitch).

Sponsors

Martini-Klinik am UKE GmbH
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Declaration of consent signed * Minimum age 18 years * localised prostate carcinoma * planned DVRP with bilateral lymphadenectomy

Exclusion criteria

* patient's lack of capacity to consent * ORP * no planned PLND * metastatic prostate cancer * ASA status \>3

Design outcomes

Primary

MeasureTime frameDescription
rate of lymphoceles requiring intervention after RARPone year follow-upClavien-Dindo \>2°

Secondary

MeasureTime frameDescription
total lymphocele rate after RARPone year follow-upClavien-Dindo
other complications ≥ grade IIIa according to Clavien-Dindo after RARPone year follow-upClavien-Dindo
continence rates after RARPone year folow-upEPIC

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026